![ISPOR 2024 May 5-8, 2024 | Atlanta, GA, USA. Early Registration Rate expires March 28.]({"type":"image" , "src" : "/sda/112343/IJME-March-May.jpg"})
References
- MS Trust. 2012. http://www.mstrust.org.uk/atoz/prevalence_incidence.jsp. Accessed 11 Jun 2013
- Lungaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon b-1a using an electronic auto injection device: a multicentre, pen-label, phase IV study. BMC Neurol 2012;12:7
- Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006;113:156-62
- Devonshire V, Arbizu T, Borre B, et al. Patient rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol 2010;10:28
- Deleu D, Alsharoqi I, Al Jumah MA, et al. Will new injection devices for interferon beta-1a s.c. Affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East. Int J Neurosci 2011;121:171-5
- Verdun di Cantogno E, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Preference and Adherence 2011;5:173-80
- Mendel R, Traut-Mattausch E, Frey D, et al. Do physicians’ recommendations pull patients away from their preferred treatment options? Health Expectations 2011;15:23-31
- The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
- Ryan M. Discrete choice experiments in health care: NICE should consider using them for patient centred evaluations of technologies. BMJ 2004;328:360-1
- Lancaster K. A new approach to consumer theory. J Polit Econ 1966;74:132-57
- Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. Brit Med J 2000;320:1530-3
- Louviere JJ, Hensher D, Swait J. Stated choice methods, analysis and applications.: Cambridge University Press, 2000. http://catdir.loc.gov/catdir/samples/cam031/00023024.pdf. Accessed 11 Jun 2013
- Dumas H, Panayiotopoulos P, Parker D, et al. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord 2006;6:5
- Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adgerence Project (GAP): a multicentre observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
- Schwartz C, Vollmer T, Lee H; North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 1999;1:63-70
- Hohol MJ, Orav E, Weiner H. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995;45:251-5
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52
- Grytten N, Måseide P. ‘When I am together with them I feel more ill.' The stigma of multiple sclerosis experienced in social relationships. Chronic Illness 2006;2:195
- Zwibel H, Pardo G, Smith S, et al. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol 2011;258:402-11